BL
BLFS
BIOLIFE SOLUTIONS INC
$24.15
+0.62%
$1.2B
No data for this timeframe.
Vol
Market Cap$1.2B
Cap SizeSmall Cap
Inst. Holders7 funds
Inst. Value$155.4M
Inst. Activity1 buys / 1 sells
Insider Activity0B / 9S
Insider Net $-$2.1M
SEC Reports3
Exchange Nasdaq·Sector Electromedical & Electrotherapeutic Apparatus·Inc. DE·CIK 0000834365·Prev Close $24.00
Recent Activity
May 7, 2026
earnings_calendar
BLFS Q1 2026 Earnings Scheduled — 2026-05-07
Apr 28, 2026
SEC
BioLife Solutions filed Amendment No. 1 to its 2025 10-K solely to add Part III items (directors, executive compensation
10-K/A — Impact 2/10
Apr 8, 2026
Insider
Wichterman Troy sold 844 shares
Chief Financial Officer @ $19.27 ($16.3K)
Apr 8, 2026
Insider
Berard Todd sold 293 shares
Chief Marketing Officer @ $19.27 ($5.6K)
Apr 8, 2026
Insider
Mathew Aby J. sold 515 shares
EVP & Chief Scientific Officer @ $19.27 ($9.9K)
Mar 9, 2026
SEC
Multiple C-suite executives at BioLife Solutions sold shares in a coordinated cluster over the past week, with total ope
CLUSTER — Impact 6/10
Mar 5, 2026
SEC
Four C-suite executives at BioLife Solutions — including the CFO and Chief Quality and Operations Officer — sold shares
CLUSTER — Impact 3/10
Inst.
FMR LLC — ADD
1,548,194 shares ($37.4M)
Price Targets
Historical data — last covering-analyst action Dec 2025. No current recommendation available.
$32.30 (Dec 2025)
Current $24.15
Low $30.00
Median $32.50
High $34.00
10 analysts
$30.00
$34.00
Analyst Ratings
4Strong Buy
11Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Dec 29, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Nov 24, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.06 ▲ +140.0% | $0.06 — $0.06 | 525% YoY | 1 |
| Next Q | $0.07 ▲ +75.0% | $0.07 — $0.07 | 67% YoY | 1 |
| Current FY | $0.25 ▲ +85.2% | $0.25 — $0.25 | 92% YoY | 1 |
| Next FY | $0.29 | $0.25 — $0.33 | 16% YoY | 2 |
Latest Reports
NEUTRAL
10-K/A
2/10
BioLife Solutions filed Amendment No. 1 to its 2025 10-K solely to add Part III items (directors, executive compensation
Apr 28, 2026
BEARISH
CLUSTER
6/10
Multiple C-suite executives at BioLife Solutions sold shares in a coordinated cluster over the past week, with total ope
Mar 9, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $74.7M | — |
| FMR LLC | $37.4M | ADD |
| MORGAN STANLEY | $12.9M | ADD |
| BANK OF AMERICA CORP | $12.6M | TRIM |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $9.2M | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 8, 2026 | Wichterman Troy | F | $16.3K |
| Apr 8, 2026 | Berard Todd | F | $5.6K |
| Apr 8, 2026 | Mathew Aby | F | $9.9K |
| Mar 23, 2026 | Foster Karen | SELL | $49.4K |
| Mar 19, 2026 | Wichterman Troy | F | $71.7K |
7 institutional holders with $155.4M total value (6,425,358 shares) as of 2025-Q4. Top holders: VANGUARD, FMR, MORGAN.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 3,087,386 | $74.7M | 48.1% | — |
| 2 | FMR LLC | 1,548,194 | $37.4M | 24.1% | ADD +52.4% |
| 3 | MORGAN STANLEY | 535,040 | $12.9M | 8.3% | ADD +25.1% |
| 4 | BANK OF AMERICA CORP /DE/ | 521,327 | $12.6M | 8.1% | TRIM -28.8% |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 379,741 | $9.2M | 5.9% | NEW |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 224,700 | $5.4M | 3.5% | TRIM -37.2% |
| 7 | WELLS FARGO & COMPANY/MN | 128,970 | $3.1M | 2.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FMR LLC | ADD | 1,015,771 | 1,548,194 | +52.4% | $37.4M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 15,800 | 0 | -100.0% | $0.00 | 2025-Q4 |
| FMR LLC | DOUBLED | 3,081 | 1,015,771 | +32868.9% | $25.9M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 671,731 | 478,273 | -28.8% | $12.2M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 306,100 | 192,200 | -37.2% | $4.9M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 15,800 | — | $403.1K | 2025-Q3 |
| MORGAN STANLEY | ADD | 417,936 | 523,020 | +25.1% | $11.3M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 47,000 | 306,100 | +551.3% | $6.6M | 2025-Q2 |
| FMR LLC | NEAR_EXIT | 14,128 | 3,081 | -78.2% | $66.4K | 2025-Q2 |
| UBS Group AG | TRIM | 332,932 | 216,554 | -35.0% | $4.9M | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 298,586 | 127,802 | -57.2% | $2.9M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 21,100 | 47,000 | +122.7% | $1.1M | 2025-Q1 |
| UBS Group AG | DOUBLED | 14,930 | 332,932 | +2130.0% | $8.6M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 54,380 | 21,100 | -61.2% | $547.8K | 2024-Q4 |
| MORGAN STANLEY | ADD | 292,135 | 393,330 | +34.6% | $9.8M | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 319,959 | — | $8.0M | 2024-Q3 |
13 unique insiders with 9 transactions. Net insider value: -$2.1M ($0.00 bought, $2.1M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 8, 2026 | Wichterman Troy | Chief Financial Officer | F | 844 | $19.27 | $16.3K |
| Apr 8, 2026 | Berard Todd | Chief Marketing Officer | F | 293 | $19.27 | $5.6K |
| Apr 8, 2026 | Mathew Aby J. | EVP & Chief Scientific Officer | F | 515 | $19.27 | $9.9K |
| Mar 23, 2026 | Foster Karen A. | Chief Quality and Operations | SELL | 2,577 | $19.17 | $49.4K |
| Mar 19, 2026 | Wichterman Troy | Chief Financial Officer | F | 3,749 | $19.12 | $71.7K |
| Mar 19, 2026 | Foster Karen A. | Chief Quality and Operations | F | 1,907 | $19.12 | $36.5K |
| Mar 19, 2026 | Berard Todd | Chief Marketing Officer | F | 1,879 | $19.12 | $35.9K |
| Mar 19, 2026 | Werner Sean | Chief Technology Officer | F | 1,681 | $19.12 | $32.1K |
| Mar 19, 2026 | Mathew Aby J. | EVP & Chief Scientific Officer | F | 2,255 | $19.12 | $43.1K |
| Mar 19, 2026 | Aebersold Sarah | Chief Human Resources Officer | F | 931 | $19.12 | $17.8K |
| Mar 19, 2026 | DE GREEF RODERICK | President and CEO | F | 11,101 | $19.12 | $212.3K |
| Mar 9, 2026 | Foster Karen A. | Chief Quality and Operations | SELL | 500 | $20.00 | $10.0K |
| Mar 5, 2026 | Foster Karen A. | Chief Quality and Operations | SELL | 96,923 | $20.15 | $2.0M |
| Mar 3, 2026 | Aebersold Sarah | Chief Human Resources Officer | SELL | 219 | $20.74 | $4.5K |
| Mar 3, 2026 | Berard Todd | Chief Marketing Officer | SELL | 353 | $20.74 | $7.3K |
| Mar 3, 2026 | Werner Sean | Chief Technology Officer | SELL | 111 | $20.74 | $2.3K |
| Mar 3, 2026 | Mathew Aby J. | EVP & Chief Scientific Officer | SELL | 529 | $20.74 | $11.0K |
| Mar 3, 2026 | Foster Karen A. | Chief Quality and Operations | SELL | 418 | $20.74 | $8.7K |
| Mar 3, 2026 | Wichterman Troy | Chief Financial Officer | SELL | 588 | $20.74 | $12.2K |
| Feb 24, 2026 | Berard Todd | Chief Marketing Officer | A | 20,096 | $0.00 | $0.00 |
| Feb 24, 2026 | Foster Karen A. | Chief Quality and Operations | A | 32,112 | $0.00 | $0.00 |
| Feb 24, 2026 | GOSWAMI JOYDEEP | Director | A | 8,170 | $0.00 | $0.00 |
| Feb 24, 2026 | DuRoss Amy | Director | A | 8,170 | $0.00 | $0.00 |
| Feb 24, 2026 | Werner Sean | Chief Technology Officer | A | 24,116 | $0.00 | $0.00 |
| Feb 24, 2026 | Coste Catherine | Director | A | 8,170 | $0.00 | $0.00 |
| Feb 24, 2026 | Hunt Anthony | Director | A | 8,170 | $0.00 | $0.00 |
| Feb 24, 2026 | Ellingson Rachel | Director | A | 8,170 | $0.00 | $0.00 |
| Feb 24, 2026 | Wichterman Troy | Chief Financial Officer | A | 31,150 | $0.00 | $0.00 |
| Feb 24, 2026 | DE GREEF RODERICK | President and CEO | A | 118,730 | $0.00 | $0.00 |
| Feb 24, 2026 | Mathew Aby J. | EVP & Chief Scientific Officer | A | 20,096 | $0.00 | $0.00 |
| Feb 24, 2026 | Aebersold Sarah | Chief Human Resources Officer | A | 23,548 | $0.00 | $0.00 |
| Feb 24, 2026 | MOORE TIMOTHY L. | Director | A | 8,170 | $0.00 | $0.00 |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 2 neutral. Avg impact: 3.7/10.
NEUTRAL
10-K/A
2/10
BioLife Solutions filed Amendment No. 1 to its 2025 10-K solely to add Part III items (directors, ex
Apr 28, 2026
BEARISH
CLUSTER
6/10
Multiple C-suite executives at BioLife Solutions sold shares in a coordinated cluster over the past
Mar 9, 2026
NEUTRAL
CLUSTER
3/10
Four C-suite executives at BioLife Solutions — including the CFO and Chief Quality and Operations Of
Mar 5, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Dec 2025): 94% buy across 16 analysts — 4 strong buy, 11 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Dec 2025. No current recommendation available.
$32.30 mean target (Dec 2025)
$30.00 Low
$34.00 High
| Metric | Value |
|---|---|
| Current Price | $24.15 |
| Target Low | $30.00 |
| Target Mean | $32.30 |
| Target Median | $32.50 |
| Target High | $34.00 |
| # Analysts | 10 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.06 | $0.06 | $0.06 | 525.0% | +140.0% | — | $0.0B | 8.1% | 1 |
| Next Q 2026-09-30 |
$0.07 | $0.07 | $0.07 | 66.9% | +75.0% | — | $0.0B | 3.5% | 1 |
| Current FY 2026-12-31 |
$0.25 | $0.25 | $0.25 | 91.9% | +85.2% | 0↑ 1↓ | $0.1B | 18.2% | 1 |
| Next FY 2027-12-31 |
$0.29 | $0.25 | $0.33 | 16.0% | +0.0% | 1↑ 0↓ | $0.1B | 17.8% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.060 | |
| 7d ago | $0.025 | +0.035 |
| 30d ago | $0.025 | +0.035 |
| 60d ago | $0.025 | +0.035 |
| 90d ago | $0.020 | +0.040 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Dec 29, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Nov 24, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 4 | 11 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 4 | 11 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 4 | 11 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 4 | 11 | 1 | 0 | 0 | 94% | |
| Jan 1, 2026 | 4 | 11 | 1 | 0 | 0 | 94% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 7, 2026
earnings_calendar
BLFS Q1 2026 Earnings Scheduled — 2026-05-07
Feb 26, 2026
earnings_calendar
BLFS Q4 2025 Earnings After Market Close — 2026-02-26